2nd Translational Research Conference: Acute Lymphoblastic Leukaemia

CONFERENCE UPDATE: novel coronavirus (COVID-19)

ESH 2nd Translational Research Conference
Acute Lymphoblastic Leukaemia: MOVING ONLINE
#ESHALL2021

May 7-9, 2021
Chairs: Jan Cools, Hervé Dombret, Adele Fielding, Mark Litzov

 
ABOUT THE E-CONFERENCE:

In view of continuing COVID-19 related challenges and uncertainties, ESH has decided to hold the 2nd Translational Research Conference on ALL as a virtual event.

An outstanding faculty of distinguished global experts will present the most recent advances and new perspectives in the field of ALL.

The plenary E-Conference programme is designed to place emphasis on leading-edge basic and clinical research. The presentation of unpublished data is encouraged. Ample time is deliberately provided for scientific discussion and interaction.

Registered participants will further benefit from opportunities for informal scientific interaction with the world’s leading experts in the field during closed Meet the Expert sessions and E-Mentored Posters Walks.

Participants will be joining us from all over the world and from different time zones. To make sure that everyone has access to the full scientific programme at a convenient hour, registration will allow participants to join both the LIVE PROGRAMME  and the PROGRAMME ON DEMAND.

– The “Live Programme” is to be found on programme page. It will be streamed live CET time, as indicated. It will include lectures, roundtable discussions, Meet the Expert sessions, interactive panel discussions, voting and Q&A periods, and Mentored Poster Walks. It will also include some pre-recorded lectures that will be streamed live, followed by their corresponding fully live Q&A period.

– The “Programme on Demand” available as of April 27, 2021, will initially include the pre-recorded components of the scientific programme. It will be progressively enriched by the meeting’s live, interactive components which will be recorded real time during the meeting.

The Virtual platform will remain open from April 27 until June 9, 2021 so that participants can view and review the programme’s full scientific content at times convenient to them.

We have selected a platform with the technical capacity and environment which we feel responds to ESH objectives in terms of learning, scientific interaction and conviviality.

We hope that you will be interested in joining us for this ESH E-Conference on ALL,

In the meantime Stay Safe!
The ESH Team
 

ABOUT THE CONFERENCE:

Major recent advances in the knowledge of the biological underpinning of acute lymphoblastic leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events. 

 At the same time, the clinical management of the disease has improved in both children and adults thanks to the routine monitoring of measurable residual disease (MRD), the administration of intensified risk-adapted chemotherapy, the introduction of targeted therapies and antibodies, and the remarkable efficacy of antibody-drug conjugates (ADCs), bi-specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.

This intense research activity has led to major improvements in patient outcome, while also providing important proofs of concept for the treatment of cancer in general. It has also made ALL a fascinating disease to study.

The translational scientific programme of the 2^nd ESH International Conference ALL is designed to provide ample time and opportunities for discussion with global authorities in the field.

 
LEARNING OBJECTIVES:

Upon completion of this CME activity, participants should:

• Learn how to optimally diagnose and classify ALL by combining modern diagnosis algorithms and early MRD monitoring for the rapid delivery of the right treatment to the right patient;
• Review conventional therapeutic options with a focus on the role of allogeneic haemopoietic stem cell transplantation;
• Learn how to optimize the management of individual patients on the basis of individual drug metabolism, tolerance and toxicity;
• Acquire improved knowledge of new, emerging targeted or immunologic treatments and understand how they may be combined or how they could eventually replace current conventional treatment options.

 
SCIENTIFIC TOPICS:

• Biology of B-cell precursor all
• Biology of T-cell all
• Minimal residual disease monitoring
• Individualized management of all
• New advances in all
• Car T-cells & allogeneic hsct
• Frontline incorporation of bites and adcs
• T-cell all and lymphoblastic lymphoma
• Ph and ph-like all

THE PROGRAMME WILL INCLUDE:

• Plenary Sessions
• Panel Discussions
• Debates
• Poster Walks
• Meet the Expert Sessions
• Keynote lectures

DEADLINE FOR ABSTRACTS: MARCH 3rd, 2021

Abstracts are eligible to be selected for an oral or a poster presentation.

 Abstracts:

• Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured. 
• Maximum number of words: 500 
• Your abstract will be submitted to peer review.

N/A

N/A

The registration fee for the ESH 2nd Translational Research e-Conference on Acute Lymphoblastic Leukaemia is free.

Meet the Expert sessions:  Registration fee:  20€
These sessions will be open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats will be available in each session and pre-registration will therefore be required.